Healionics is addressing the critical need for improved means of dialysis access in patients with kidney failure. We have a synthetic vascular graft (artificial blood vessel) ready for human study and an exciting product pipeline, based on our platform STAR® biomaterial which can improve the performance of wide variety of implanted devices by preventing both infection & scarring. Healionics has 25 patents issued or pending.
Healionics, located in Seattle, has strong connections and collaboration with the exceptional expertise developed via University of Washington’s key role in device and clinical innovations for treatment of kidney failure. These include the first blood access device which made long-term dialysis possible, early dialysis machines, and the first outpatient dialysis center. The area is also home to the Kidney Research Institute and Center for Dialysis Innovation.